Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sánchez, J. E. G.
Right arrow Articles by Martínez, M. J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sánchez, J. E. G.
Right arrow Articles by Martínez, M. J. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 283-285
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones

José Elías García Sáncheza,*, Natalia García Sáenza, Manuel Rodríguez Rincónb, Ignacio Trujillano Martína, Enrique García Sáncheza and María José Fresnadillo Martíneza

a Departamento de Microbiología and b Servicio de Medicina Interna, Hospital Universitario, Paseo de San Vicente 108, 37007 Salamanca, Spain

The in vitro activities of mupirocin, quinupristin/dalfopristin, linezolid, eperezolid, sitafloxacin, clinafloxacin, moxifloxacin, amoxycillin, metronidazole and clarithromycin were tested at pH 7.4 against 57 strains of Helicobacter pylori. The most active agents (mupirocin, sitafloxacin and clinafloxacin) were also tested for activity at pH 5.4 against the same strains. Mupirocin was very active at pH 7.4 and 5.4 (MIC90 0.25 and 0.12 mg/L, respectively). Quinupristin/dalfopristin, linezolid and eperezolid had low activity (MIC90 4, 8 and 4 mg/L, respectively). Sitafloxacin (MIC90 <= 0.008 mg/L) was the most active fluoroquinolone, while clinafloxacin (MIC90 0.12 mg/L) and moxifloxacin (MIC90 2 mg/L) were least active.

* Corresponding author. Tel: +34-923-264825; Fax: 34-923-262261; E-mail: joegas{at}gugu.usal.es


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
C.-H. Kuo, H.-M. Hu, F.-C. Kuo, P.-I. Hsu, A. Chen, F.-J. Yu, P.-Y. Tsai, I.-C. Wu, S.-W. Wang, C.-J. Li, et al.
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial
J. Antimicrob. Chemother., May 1, 2009; 63(5): 1017 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Suzuki, T. Nishizawa, H. Muraoka, and T. Hibi
Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1720 - 1721.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Van den Bulck, A. Decostere, I. Gruntar, M. Baele, B. Krt, R. Ducatelle, and F. Haesebrouck
In Vitro Antimicrobial Susceptibility Testing of Helicobacter felis, H. bizzozeronii, and H. salomonis
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2997 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Wirtz, J. Kleeff, S. Swoboda, I. Halaceli, H. K. Geiss, T. Hoppe-Tichy, M. W. Buchler, and H. Friess
Moxifloxacin penetration into human gastrointestinal tissues
J. Antimicrob. Chemother., May 1, 2004; 53(5): 875 - 877.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Tankovic, C. Lascols, Q. Sculo, J.-C. Petit, and C.-J. Soussy
Single and Double Mutations in gyrA but Not in gyrB Are Associated with Low- and High-Level Fluoroquinolone Resistance in Helicobacter pylori
Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3942 - 3944.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Tanaka, E. Isogai, H. Isogai, S. Hayashi, K. Hirose, K. Kimura, T. Sugiyama, and K. Sato
Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori
J. Antimicrob. Chemother., June 1, 2002; 49(6): 1039 - 1040.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. W. Minehart and A. F. Chalker
In vitro activity of gemifloxacin against Helicobacter pylori
J. Antimicrob. Chemother., March 1, 2001; 47(3): 360 - 361.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.